2. Hostoffer R.W., Joseph N.I. Immunoglobulin E. 2023. In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing. 2024. PMID: 29489151.

3. Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229–63.

https://doi.org/10.3322/caac.21834. PMID: 38572751.

4. Agress A., Oprea Y., Roy S. et al. The association between malignancy, immunodeficiency, and atopy in IgE-deficient patients. J Allergy Clin Immunol Pract. 2024; 12(1): 185–94.

https://doi.org/10.1016/j.jaip.2023.10.026. PMID: 37863316.

5. Zhang J., Ni J., Kong W. et al. Various clinical manifestations of 223 patients with IgE deficiency in a tertiary hospital in China: A cross-sectional study. Medicine (Baltimore). 2024; 103(24): e38397.

https://doi.org/10.1097/MD.0000000000038397. PMID: 38875431. PMCID: PMC11175936.

6. Al S., Asilsoy S., Uzuner N. et al. Is there a clinical significance of very low serum immunoglobulin E level? J Clin Immunol. 2021; 41(8): 1893–901.

https://doi.org/10.1007/s10875-021-01127-y. PMID: 34478043.

7. Weller K.N., McDonnell J.C., Albert J.M. et al. Increased hazard risk of first malignancy in adults with undetectable serum IgE: A retrospective cohort study. J Clin Immunol. 2023; 43(3): 568–77.

https://doi.org/10.1007/s10875-022-01401-7. PMID: 36380194.

8. Ferastraoaru D., Jordakieva G., Jensen-Jarolim E. The other side of the coin: IgE deficiency, a susceptibility factor for malignancy occurrence. World Allergy Organ J. 2021; 14(1): 100505.

https://doi.org/10.1016/j.waojou.2020.100505. PMID: 33664932. PMCID: PMC7887422.

9. Bozek A., Jarzab J., Mielnik M. et al. Can atopy have a protective effect against cancer? PLoS One. 2020; 15(2): e0226950.

https://doi.org/10.1371/journal.pone.0226950. PMID: 32015564. PMCID: PMC6996965.

10. De Monte L., Clemente F., Ruggiero E. et al. Pro-tumor Tfh2 cells induce detrimental IgG4 production and PGE2-dependent IgE inhibition in pancreatic cancer. EBioMedicine. 2023; 97: 104819.

https://doi.org/10.1016/j.ebiom.2023.104819. PMID: 37776595. PMCID: PMC10542011.

11. Singh N., Mott S.L., Sutamtewagul G. et al. Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. EJHaem. 2020; 1(2): 537–44.

https://doi.org/10.1002/jha2.95. PMID: 35845010. PMCID: PMC9176078.

12. Dmitrieva N.I., Walts A.D., Nguyen D.P. et al. Impaired angiogenesis and extracellular matrix metabolism in autosomal-dominant hyper-IgE syndrome. J Clin Invest. 2020; 130(8): 4167–81.

https://doi.org/10.1172/JCI135490. PMID: 32369445. PMCID: PMC7410079.

13. Mohammadi T., Azizi G., Rafiemanesh H. et al. A systematic review regarding the prevalence of malignancy in patients with the hyper-IgE syndrome. Clin Exp Med. 2023; 23(8): 4835–59.

https://doi.org/10.1007/s10238-023-01228-5. PMID: 37924455.

14. Akinboro A.O., Onigbinde M.O., Oiwoh S.O. et al. Hyper-immunoglobulin E syndrome and squamous cell carcinoma of the lower lip: A case report. West Afr J Med. 2021; 38(2): 180–84. PMID: 33641156.

15. (Zhang M., Zhang W., Zhang Y., Zhang Y. Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: A case report and literature review. Zhonghua Xue Ye Xue Za Zhi. 2020; 41(10): 865–68 (In Chinese)).

https://doi.org/10.3760/cma.j.issn.0253-2727.2020.10.014. PMID: 33190447. PMCID: PMC7656068.

16. Khalil M., Sharaf Eldin A., Sadek A. et al. Serum total IgE as immunological marker in patients with chronic hepatitis B virus infection, and hepatitis B related hepatocellular carcinoma. Egypt J Immunol. 2023; 30(1): 96–104. PMID: 36592385.

17. Turner M.C., Radzikowska U., Ferastraoaru D.E. et al. AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus-A joint EAACI-EANO position paper. Allergy. 2024; 79(6): 1419–39.

https://doi.org/10.1111/all.15994. PMID: 38263898.

18. Guerra G., Nakase T., Kachuri L. et al. Association of immunoglobulin E levels with glioma risk and survival. medRxiv (Preprint). 2024: 2024.05.09.24307132.

https://doi.org/10.1101/2024.05.09.24307132. PMID: 38766059. PMCID: PMC11100947.

19. Byakwaga H., Barbachano-Guerrero A., Wang D. et al. Association between immunoglobulin E levels and Kaposi sarcoma in African adults with human immunodeficiency virus infection. J Infect Dis. 2021; 223(1): 101–8.

https://doi.org/10.1093/infdis/jiaa340. PMID: 32561934. PMCID: PMC7781465.

20. Korhonen J., Siiskonen H., Haimakainen S. et al. Expression of mast cell tryptase and immunoglobulin E is increased in cutaneous photodamage: Implications for carcinogenesis. J Dermatolog Treat. 2024; 35(1): 2307488.

https://doi.org/10.1080/09546634.2024.2307488. PMID: 38291602.

21. Komulainen J., Siiskonen H., Haimakainen S. et al. Patients with a history of atopy have fewer cutaneous melanomas than those without atopy: A cross-sectional study in 496 patients at risk of skin cancers. Melanoma Res. 2023; 33(3): 218–29.

https://doi.org/10.1097/cmr.0000000000000887. PMID: 36847301.

22. Iordache A., Balica N.C., Horhat I.D. et al. Allergic rhinitis associated with nasal polyps and rhinosinusitis – histopathological and immunohistochemical study. Rom J Morphol Embryol. 2022; 63(2): 413–19.

https://doi.org/10.47162/RJME.63.2.12. PMID: 36374146. PMCID: PMC9801672.

23. Kadin M.E., Hamilton R.G., Vonderheid E.C. Evidence linking atopy and staphylococcal superantigens to the pathogenesis of lymphomatoid papulosis, a recurrent CD30+ cutaneous lymphoproliferative disorder. PLoS One. 2020; 15(2): e0228751.

https://doi.org/10.1371/journal.pone.0228751. PMID: 32049976. PMCID: PMC7015403.

24. Wu L., Xia M., Sun X. et al. High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia. Eur J Haematol. 2020; 105(4): 449–59.

https://doi.org/10.1111/ejh.13466. PMID: 32535947.

25. Yu C.-Y., Liu J., Qi C.-H. et al. Minimal change disease associated with gastrointestinal stromal tumor accompanied by significantly elevated serum IgE level: A case report. BMC Nephrol. 2022; 23(1): 139.

https://doi.org/10.1186/s12882-022-02775-x. PMID: 35410141. PMCID: PMC8996523.

26. Ferrari M.F., Lemonakis K., Jonsson M.F. A rare case of IgE kappa monoclonal gammopathy of undetermined significance identified in a Swedish female. Scand J Clin Lab Invest. 2021; 81(5): 385–88.

https://doi.org/10.1080/00365513.2021.1929443. PMID: 34097568.

27. Kehl N., Kilian M., Michel J. et al. IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells. J Immunother Cancer. 2022; 10(10): e005815.

https://doi.org/10.1136/jitc-2022-005815. PMID: 36252999. PMCID: PMC9577923.

28. Chen Y., Chen Y., Zhou Y. et al. Defects and countermeasures in laboratory diagnosis of rare IgE multiple myeloma. Clin Chim Acta. 2022; 532: 37–44.

https://doi.org/10.1016/j.cca.2022.05.011. PMID: 35594922.

29. Galakhoff N., Leven C., Eveillard J.R. et al. A case of IgE myeloma transformed into IgE-producing plasma cell leukaemia. Biochem Med (Zagreb). 2020; 30(1): 010801. https://doi.org/10.11613/BM.2020.010801. PMID: 31839726. PMCID: PMC6904968.

30. Caiado J., Castells M.C. Drug desensitizations for chemotherapy: Safety and efficacy in preventing anaphylaxis. Curr Allergy Asthma Rep. 2021; 21(6): 37.

https://doi.org/10.1007/s11882-021-01014-x. PMID: 34232411.

31. Barrios D.M., Phillips G.S., Geisler A.N. et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol. 2021; 32(6): 736–45.

https://doi.org/10.1016/j.annonc.2021.02.016. PMID: 33667669. PMCID: PMC9282165.

32. Ramos-Martinez E., García-Vazquez F.J., Falfán-Valencia R. et al. The type 2 inflammatory response favors recognition of tumor antigens by IgE in breast cancer. Cancer Rep (Hoboken). 2024; 7(2): e2002.

https://doi.org/10.1002/cnr2.2002. PMID: 38389406. PMCID: PMC10884619.

33. McCraw A.J., Chauhan J., Bax H.J. et al. Insights from IgE immune surveillance in allergy and cancer for anti-tumour IgE treatments. Cancers (Basel). 2021; 13(17): 4460.

https://doi.org/10.3390/cancers13174460. PMID: 34503270. PMCID: PMC8431713.

34. Pellizzari G., Bax H.J., Josephs D.H. et al. Harnessing therapeutic IgE antibodies to re-educate macrophages against cancer. Trends Mol Med. 2020; 26(6): 615–26.

https://doi.org/10.1016/j.molmed.2020.03.002. PMID: 32470387.

35. Markov S.D., Caffrey T.C., O’Connell K.A. et al. IgE-based therapeutic combination enhances antitumor response in preclinical models of pancreatic cancer. Mol Cancer Ther. 2021; 20(12): 2457–68.

https://doi.org/10.1158/1535-7163.MCT-21-0368. PMID: 34625505. PMCID: PMC8762606.

36. Pellizzari G., Martinez O., Crescioli S. et al. Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. J Immunother Cancer. 2021; 9(6): e002140.

https://doi.org/10.1136/jitc-2020-002140. PMID: 34112739. PMCID: PMC8194339.

37. Chauhan J., Grandits M., Palhares L.C.G.F. et al. Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4. Nat Commun. 2023; 14(1): 2192.

https://doi.org/10.1038/s41467-023-37811-3. PMID: 37185332. PMCID: PMC10130092.

38. Spicer J., Basu B., Montes A. et al. Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: A phase I trial. Nat Commun. 2023; 14(1): 4180.

https://doi.org/10.1038/s41467-023-39679-9. PMID: 37491373. PMCID: PMC10368744.